The effect of empagliflozin (sodium-glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study.
Humans
Glucosides
/ therapeutic use
Female
Male
Diabetes Mellitus, Type 2
/ drug therapy
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
Benzhydryl Compounds
/ therapeutic use
Middle Aged
Blood Glucose
/ drug effects
Aged
Osteoporosis
/ drug therapy
Bone Density
/ drug effects
Glycated Hemoglobin
/ metabolism
Treatment Outcome
Calcium
/ blood
Osteoporotic Fractures
/ prevention & control
Phosphorus
/ blood
Diabetic osteoporosis
Empagliflozin
Fracture
Symptomatic treatment
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
07 Oct 2024
07 Oct 2024
Historique:
received:
04
07
2024
accepted:
23
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
7
10
2024
Statut:
epublish
Résumé
Diabetic osteoporosis (DOP) is a metabolic disease that occurs in patients with diabetes due to insufficient insulin secretion. This condition can lead to sensory neuropathy, nephropathy, retinopathy, and hypoglycemic events, which can increase the risk of fractures. This study aimed to assess the effectiveness of Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, in treating diabetic osteoporosis (DOP) and preventing fractures. This quasi-experimental study enrolled 100 patients with diabetic osteoporosis from February 2023 to February 2024. Participants were randomly assigned to an intervention group (n = 50) and a control group (n = 50). The intervention group received Empagliflozin in combination with symptomatic treatment, while the control group received only symptomatic treatment. The treatment duration was six months. Fasting blood glucose (FBG), 2-hour postprandial blood glucose (2 h PG), glycosylated hemoglobin A1c (Hb A1c), bone mineral density (BMD), serum phosphorus and calcium concentration were measured after the intervention and the incidence of fracture was followed up for 12 months. The data were analyzed using SPSS 23. Descriptive statistics (mean, standard deviation, and percentage) and analytical methods (t test, Chi square) were also used to analyze the data. After six months of treatment, the intervention group exhibited significantly lower levels of FBG (P < 0.001), 2 h-PG (P = 0.001), and HbA1c (P < 0.001) than the control group. Additionally, bone mineral density, serum phosphorus, and calcium levels were significantly higher in the intervention group (P < 0.001). After a 12-months follow-up, the incidence of fractures in the intervention group was 2%, while it was 16.33% in the control group (P < 0.05). Empagliflozin, when combined with symptomatic treatment, demonstrates a positive clinical effect in patients with diabetic osteoporosis. The treatment effectively improves blood glucose metabolism, bone mineral density, and phosphorus and calcium metabolism, ultimately leading to a significant reduction in the incidence of fracture.
Identifiants
pubmed: 39375646
doi: 10.1186/s12891-024-07900-5
pii: 10.1186/s12891-024-07900-5
doi:
Substances chimiques
empagliflozin
HDC1R2M35U
Glucosides
0
Sodium-Glucose Transporter 2 Inhibitors
0
Benzhydryl Compounds
0
Blood Glucose
0
Glycated Hemoglobin
0
hemoglobin A1c protein, human
0
Calcium
SY7Q814VUP
Phosphorus
27YLU75U4W
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
793Informations de copyright
© 2024. The Author(s).
Références
Fu W, Fan J. Intervention effect of exercise rehabilitation therapy on patients with type 2. Am J Tran Res. 2021;13(4):3400–8.
Ma P. Comprehensive nursing care of patients with type 2. Contemp J Clin Med. 2021;34(2):105–6.
An Y, Zhang H, Wang C, Jiao F, Xu H et al. Activation of ROS/MAPKs/NF-κB/NLRP3 and inhibition of efferocytosis in osteoclast-mediated. FASEB J. 2019;33(11):12515-27.
Paschou S, Vryonidou A, et al. Diabetes mellitus and osteoporosis. Minerva Endocrinol. 2019;44(4):333–5.
Chen P, Li Z, Hu Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review. BMC Public Health. 2016;16(1039).
Asokan A, Jaganathan J, Philip R, Soman R, Sebastian S, Pullishery F. Evaluation of bone mineral density among type 2 diabetes mellitus patients in South Karnataka. J Nat Sc Biol Med. 2017;8:94–8.
doi: 10.4103/0976-9668.198363
Yuhao S, Cenyi W, Yang G, Guihua X, Yong M. Prevalence of osteoporosis in patients with type 2 diabetes Mellitus in the Chinese mainland: a systematic review and Meta-analysis. Iran J Public Health. 2019;48(7):1202–14.
Brown J. Al L-Te Treat Postmenopausal Osteoporos Endocrinol Metab (Seoul). 2021;36(3):544–52.
doi: 10.3803/EnM.2021.301
Ala M, Jafari R, Dehpour A et al. Diabetes Mellitus and Osteoporosis Correlation: Challenges and Hopes. Curr Diabetes Rev. 2020;16(9):984–1001.
Wang X, Ma H, Sun J, Zheng T, Zhao P, Li H, et al. Mitochondrial Ferritin Deficiency promotes Osteoblastic Ferroptosis Via Mitophagy in Type 2. DOP Biol Trace Elem Res. 2022;1:298–307.
doi: 10.1007/s12011-021-02627-z
Vilaca T, Eastell R, Schini M et al. Osteoporosis in men Lancet Diabetes Endocrinol. 2022;10(4):273 – 83.
Mohsin S, Baniyas M, AlDarmaki R, Tekes K, Kalász H, Adeghate E et al. An update on therapies for the treatment of diabetes-induced osteoporosis. Expert Opin Biol Ther. 2019(9):937–48.
Wang X, Gao H, Wang H et al. Clinical effect of Guli capsule associated with routine treatment on climacteric. Proprietary Chin Med. 2022;44(5):1479-83.
Jiang C, Gao M, al e. Effects of Lilarutide associated with Alfacalcidol on blood glucose, bone metabolism, SFRP5 and IGF-1 in elderly patients with type 2 diabetes mellitus complicated with osteoporosis. Clin Med Res Pract. 2022;7(14):63–6.
Dai H, Li H, Su X, Dai Z, Zhu L et al. Predictive value of senile nutritional risk index for type 2 DOP. Zhejiang Med. 2022;44(8):831-6.
Meng B, Chen B, Fan Y, Chang B et al. Effects of Atto vastatin associated with alendronate on bone metabolism and inflammation related factors in patients with T2DM complicated with osteoporosis. Chin J Endocr Surg 2022;16(2):226 – 30.
Paschou SA, Dede AD, Anagnostis PG, Vryonidou A, Morganstein D, Goulis DG. Type 2 diabetes and osteoporosis: a guide to Optimal Management. J Clin Endocrinol Metab. 2017;102(10):3621–34.
doi: 10.1210/jc.2017-00042
Tang R, Luo R, Song H, Xu X, Qi T. Reticular Meta analysis of the effect of sodium-glucose symporter inhibitor on cardiorenal outcome in patients with diabetes mellitus. Chin Pharm Ind. 2022;31(6):110–4.
Kocjan T, Rajic A, Janez A, Vidmar G, Orehek N, Marc J et al. Switching to Denosumab or bisphosphonates after Completion of Teriparatide treatment in women with severe postmenopausal osteoporosis Endocr Pract. 2021;27(9):941–7.
Jun S, Aon M et al. Empagliflozin and HFr EF: Known and Possible Benefits of NHE1 Inhibition. JACC Basic Transl Sci. 2019;4(7):841-4.
Association AD. Standards of Medical Care in Diabetes—2019. Abr Prim Care Providers. 2019;37(1):11–34.
Assoc DBoCM. Natl off Prev treat Diabetes National guidelines prevent treat diabetes grass-roots level [J]. Chin J Intern Med. 2022;61(3):249–62.
Osteoporosis GdtP, Chin. J Osteoporos Bone Min Dis. 2011;4(1):2–17.
Amanat S, Ghahri S, Dianatinasab A, Fararouei M, Dianatinasab M. Exercise and Type 2 diabetes. Adv Exp Med Biol. 2020;1228:91–105.
doi: 10.1007/978-981-15-1792-1_6
Ding X, long F, Chen L, et al. Interaction of tea drinking and healthy lifestyle on the prevalence of diabetes among residents aged 30 to 79 in Chongqing. Pract Prev Med. 2022;29(6):641–4.
Zhang L, Wang Q, Su H, Cheng J, et al. Exosomes from adipose derived mesenchymal stem cells alleviate DOP in rats through suppressing NLRP3 inflammasome activation in osteoclasts. J Biosci Bioeng. 2021;131(6):671–8.
doi: 10.1016/j.jbiosc.2021.02.007
Shen M, Fei Y, Sun L et al. Meta analysis of efficacy and safety of tonifying kidney and activating blood circulation when treating DOP [J]. Zhejiang J Integr Tradit Chin WestMed. 2022;32(1):75–81.
Liu Y. Changes and clinical significance of BMD and bone metabolic markers in patients with different stages of type 2 diabetic nephropathy. Syst Med. 2022;7(2):21–4.
Lan K, Wang W, Shen J et al. Analysis of bone metabolic indexes in patients with type 2 diabetes mellitus complicated with osteoporosis [J]. J Xinjiang Med Univ. 2022;45(1):70 – 4.
Ruan Z, Chen Y et al. Research progress of mesenchymal stem cell-derived exocrine in DOP [J]. Chin J Osteoporos. 2022;28(1):104-8.
Stavropoulou M, Makras P. Anastasilakis, Al e. AD Bazedoxifene for the treatment of osteoporosis. Expert Opin Pharmacother. 2019;20(10):1201–10.
doi: 10.1080/14656566.2019.1615882
Zhang J, Cai Z, Yang M, Tong L, Zhang Y et al. Inhibition of tanshinone IIA on renin activity protected against osteoporosis in diabetic mice Pharm Biol. 2020;58(1):219 – 24.
Tsai J, Lee H, David N, Eastell R, Leder B, et al. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomized, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019;7(10):767–75.
doi: 10.1016/S2213-8587(19)30255-4
Bone H, Cosman F, Miller P, Williams G, Hattersley G, Hu M, et al. ACTIVExtend: 24 months of Alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949–57.
doi: 10.1210/jc.2018-00163
Chao C, Wang J, Huang J, Chan D, Hung K, Chien K, et al. COhort of GEriatric Nephrol NTUH (COGENT) res group chronic kidney disease-related osteoporosis is associated with incident frailty among patients with diabetic kidney disease: a propensity score-matched cohort study. Osteoporos Int. 2020;31(4):699–708.
doi: 10.1007/s00198-020-05353-9
Schacter G, Leslie W, et al. Diabetes and osteoporosis: part I, Epidemiology and Pathophysiology. Endocrinol Metab Clin North Am. 2021;50(2):275–85.
doi: 10.1016/j.ecl.2021.03.005
Schacter G, Leslie W, et al. Diabetes and osteoporosis: part II, Clinical Management. Endocrinol Metab Clin North Am. 2021;50(2):287–97.
doi: 10.1016/j.ecl.2021.03.006
Liu G, Wang Z, Liu L, Zhang B, Miao Y, Yu S, et al. A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis. J Cell Biochem. 2018;119(6):4469–81.
doi: 10.1002/jcb.26550
Zhao Z. Correlation analysis of urine proteins and inflammatory cytokines with osteoporosis in patients with diabetic nephropathy. J Musculoskelet Neuronal Interact. 2018;18(3):348–53.
Qi S, He J, Han H, Zheng H et al. Anthocyanin-rich extract from black rice (Oryza sativa L Japonica) ameliorates DOP in rats Food Funct. 2019;10(9):5350-60.
Zhang Z, Ren H, Wang W, Shen G, Huang J et al. IGF-1R/β-catenin signaling axis is involved in type 2 DOP. J Zhejiang Univ Sci B. 2019;20(10):838 – 48.
Cortet B, Lucas S, Legroux-Gerot I, Penel G, Chauveau C, Paccou J, et al. Bone disorders associated with diabetes mellitus and its treatments. Joint Bone Spine. 2019;86(3):315–20.
doi: 10.1016/j.jbspin.2018.08.002
Yagi S, Aihara K, Kondo T et al. Predictors for the Treatment Effect of Sodium Glucose Co- transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus[J]. Adv Ther. 2018;35(1):124 – 34.
Yao C, Guo X, Yao W, Zhang C. ea. Cereblon (CRBN) deletion reverses streptozotocin induced DOP in mice Biochem. Biophys Res Commun. 2018;496(3):967–74.
doi: 10.1016/j.bbrc.2018.01.095
Choksi P, Gay B, Reyes-Gastelum D, Haymart M, Papaleontiou M, et al. Understanding osteoporosis screening practices in men: a Nationwide Physician Survey. Endocr Pract. 2020;26(11):1237–43.
doi: 10.4158/EP-2020-0123
Li Z, Zhao H, Chu S, Liu X, Qu X, Li J, et al. Mir-124-3p promotes BMSC osteogenesis via suppressing the GSK-3β/β-catenin signaling pathway in DOP rats in Vitro. Cell Dev Biol Anim. 2020;56(9):723–34.
doi: 10.1007/s11626-020-00502-0
Goswami R, Nair A, et al. Diabetes mellitus, vitamin D & osteoporosis: insights. Indian J Med Res. 2019;150(5):425–8.
doi: 10.4103/ijmr.IJMR_1920_19
Donnan K, Segar L. SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol. 2019;846:23–9.
doi: 10.1016/j.ejphar.2019.01.002
Taylor S, Blau J, Rother K, et al. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3(1):8–10.
doi: 10.1016/S2213-8587(14)70227-X